Compare AMCI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | MXCT |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 86.5M |
| IPO Year | N/A | 2021 |
| Metric | AMCI | MXCT |
|---|---|---|
| Price | $6.48 | $0.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 67.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.64 |
| P/E Ratio | $33.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $0.64 |
| 52 Week High | $15.75 | $3.58 |
| Indicator | AMCI | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 34.49 |
| Support Level | $5.65 | $0.75 |
| Resistance Level | $6.99 | $1.79 |
| Average True Range (ATR) | 0.65 | 0.06 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 35.71 | 67.86 |
AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.